CSL will contest FTC opposition to Talecris buyout: <a href="http://www.reuters.com/article/marketsNews/idINSYU00659620090527" rel="nofollow" target="_blank">http://www.reuters.com/article/marketsNews/idINSYU00659620090527</a> Managing Director Brian McNamee said… U.S. regulators had failed to recognise that the deal would actually boost competition in the plasma products market… I can’t imagine how it could do that.